- Home
- ARQT vs IAC Comparison
ARQT vs IAC Comparison
Compare ARQT & IAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | IAC |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARQT | IAC |
|---|---|---|
| Price | $22.18 | $37.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $34.00 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 1.2M | 956.0K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 79.97 |
| EPS | ★ N/A | N/A |
| Revenue | $376,072,000.00 | ★ $4,365,235,000.00 |
| Revenue This Year | $34.46 | N/A |
| Revenue Next Year | $29.77 | $0.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $11.86 | $29.56 |
| 52 Week High | $31.77 | $50.49 |
Technical Indicators
Market Signals| Indicator | ARQT | IAC |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 48.48 |
| Support Level | $22.56 | $34.90 |
| Resistance Level | $27.26 | $38.28 |
| Average True Range (ATR) | 0.92 | 1.06 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 22.56 | 43.30 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About IAC IAC Inc.
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.